Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications (death, mechanical ventilation or ICU care)1Detailed results will be submitted for publication to support sc…
Leqvio® (inclisiran) is the first and only approved small-interfering RNA (siRNA) low-density lipoprotein cholesterol (LDL-C) lowering treatment in Europe1-3Cardiovascular disease causes 3.9 million deaths annually in Europe, and 80% of high-risk patie…
Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1Benefit seen even in patients with the endocrine-resistant HER2-en…
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women …
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1Despite advances in chronic myeloi…
Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a complete response and the overall response rate was 83%1Longer-term median follow-up of 40 months from the JULIE…
Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1Chronic graft-versus-host disease (GvHD) is a life-threatening complication of stem cell transplants and half of patients bec…
At Novartis, we know that our impact extends beyond the lives we touch with our medicines, and the performance we deliver for our stakeholders. We aim to have a positive impact on the communities in which we work, and build trust with society.Our flags…
In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.Video of Novartis Lecture – Why …
In this fireside chat, Bertrand and Peter explore Microsoft’s health moonshots, COVID response and more.Video of Novartis Lecture – Why …
